TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
TCL Archive Cancer Telethon Attracts Small Audience, Generates Expectations-And Questions. September 12, 2008
TCL Archive In Brief: Construction Grant Application Deadline for 75-25% Funding Oct. 1; Fordham Quits April 29, 1977